The US gastrointestinal therapeutics market is driven by the increasing prevalence of digestive disorders, growing awareness of early diagnosis, and rising demand for advanced treatment options. Healthcare providers are adopting innovative therapies for conditions such as inflammatory bowel disease, gastroesophageal reflux disease, irritable bowel syndrome, and peptic ulcers to improve patient...